Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYCOPHENOLATE SODIUM vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Prophylaxis of organ rejection in renal transplant patients receiving cyclosporine and corticosteroids,Prophylaxis of organ rejection in cardiac transplant patients (off-label),Prophylaxis of organ rejection in hepatic transplant patients (off-label),Treatment of lupus nephritis (off-label)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
The terminal elimination half-life of mycophenolic acid is approximately 8-16 hours in healthy subjects and renal transplant patients. The half-life of the inactive glucuronide metabolite (MPAG) is longer (16-18 hours) and accumulates in renal impairment.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Mycophenolate sodium is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract to the active metabolite mycophenolic acid (MPA). MPA is primarily metabolized by uridine diphosphate-glucuronosyltransferase (UGT) 1A9 to the inactive phenolic glucuronide (MPAG). A minor acyl glucuronide metabolite is also formed. MPAG is excreted in the urine and can be deconjugated back to MPA via enterohepatic recirculation.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Mycophenolate sodium is excreted primarily in urine as mycophenolic acid (MPA) and its glucuronide metabolite (MPAG). Renal excretion accounts for approximately 87% of the dose, with <1% excreted as unchanged MPA. Fecal excretion represents about 6%.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Mycophenolic acid is 97% bound to serum albumin. The glucuronide metabolite (MPAG) is 82% bound.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
The apparent volume of distribution of mycophenolic acid is approximately 3.6 L/kg, indicating extensive tissue distribution. This large Vd reflects high tissue binding and distribution into extravascular spaces.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
The oral bioavailability of mycophenolate sodium enteric-coated tablets is approximately 72% relative to intravenous mycophenolate mofetil. Food reduces peak concentration (Cmax) by 30-50% but does not significantly affect total area under the curve (AUC).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
For GFR 15-29 m L/min/1.73 m2: do not exceed 720 mg orally twice daily. For GFR <15 m L/min/1.73 m2: no data; use with caution. No adjustment for GFR >=30 m L/min/1.73 m2.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No specific dose adjustment guidelines for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to limited data.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Approved for pediatric renal transplant patients >=2 years: 400 mg/m2 orally twice daily (up to a maximum of 720 mg twice daily). For bone marrow transplant patients >=2 years: 400 mg/m2 orally twice daily, starting 24 hours after graft infusion.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment recommended; elderly patients may have increased risk of adverse effects such as gastrointestinal hemorrhage and infections. Use the lowest effective dose and monitor renal function closely.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Increased risk of congenital malformations and first-trimester pregnancy loss when used during pregnancy. Females of reproductive potential must be counseled about pregnancy prevention and planning. Mycophenolate can cause fetal harm when administered to a pregnant woman. Use is contraindicated in women of childbearing potential who are not using highly effective contraception.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Immunosuppression: Increased susceptibility to infections, including opportunistic infections and reactivation of latent viruses (e.g., CMV, BK virus).,Lymphoproliferative disorders: Increased risk of post-transplant lymphoproliferative disorder (PTLD) and other malignancies.,Pregnancy: Associated with first-trimester pregnancy loss and congenital malformations; contraception counseling required.,Gastrointestinal events: Severe GI bleeding, perforation, and ulceration; monitor for symptoms.,Neutropenia: Can cause severe neutropenia; monitor complete blood counts regularly.,Vaccinations: Live vaccines should not be given during treatment; influenza vaccination may be less effective.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to mycophenolate sodium, mycophenolic acid, or any component of the formulation,Women of childbearing potential not using highly effective contraception,Pregnancy (unless no suitable alternative immunosuppressant is available)
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Take on an empty stomach (1 hour before or 2 hours after meals) to minimize variability. Avoid grapefruit juice (may increase mycophenolate exposure). No specific dietary restrictions other than consistent timing relative to meals. High-fat meals reduce Cmax and AUC; administer consistently with or without food.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of oligohydramnios, intrauterine growth restriction, and preterm birth. Use is contraindicated in pregnancy unless no alternative.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Enters breast milk; M/P ratio not established. Potential for serious adverse effects in nursing infants (e.g., immunosuppression, gastrointestinal disturbances). Contraindicated during breastfeeding.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Pharmacokinetic changes (increased clearance, decreased absorption) may require higher doses to maintain therapeutic levels; therapeutic drug monitoring recommended. Postpartum doses may need reduction due to changed pharmacokinetics.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Monitor CBC weekly during first month, then biweekly for second and third months, then monthly for first year. Consider therapeutic drug monitoring (AUC 30-60 mg·h/L) to optimize dosing and reduce toxicity. Delayed-release formulation (Myfortic) must not be crushed or chewed. Avoid concurrent antacids or bile acid sequestrants. Dose reduction required in renal impairment (e GFR <50 m L/min). Estimate using ideal body weight. Taper when discontinuing to avoid graft rejection.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take exactly as prescribed; do not stop or change dose without consulting your transplant team.,Swallow delayed-release tablets whole; do not crush, chew, or cut them.,Use reliable contraception before, during, and for 6 weeks after treatment for females; males should use condoms during and for 90 days after treatment.,Avoid live vaccines (e.g., MMR, varicella) and close contact with recently vaccinated individuals.,Report signs of infection (fever, sore throat, chills), unexplained bruising/bleeding, or GI symptoms (nausea, diarrhea, abdominal pain).,Take on an empty stomach (1 hour before or 2 hours after meals) for consistent absorption.,Avoid grapefruit juice as it may alter drug levels.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYCOPHENOLATE SODIUM vs ALFENTA, answered by our medical review team.
MYCOPHENOLATE SODIUM is a Immunosuppressant that works by Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYCOPHENOLATE SODIUM and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYCOPHENOLATE SODIUM is: 720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYCOPHENOLATE SODIUM and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYCOPHENOLATE SODIUM is classified as Category C. First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of o. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.